Krsnaa Diagnostics Reports Strong Financial Results for FY26, Highlights Growth in Retail Vertical
Krsnaa Diagnostics Limited announced its audited financial results for the quarter and year ended March 31, 2026. Management highlighted robust financial performance and emphasized the rapid growth of its retail diagnostics segment as a key structural driver for the group.On a consolidated basis, the company reported significant financial achievements for the fiscal year 2026. Yash Mutha, Managing Director, stated that the results reflect the strength of the operating model and early dividends from strategic investments.
The key financial metrics reported for the year are as follows:
| Metric | FY2026 Value | Comparison/Details |
|---|---|---|
| Consolidated Revenue | ₹7,728 million | |
| Profit After Tax (PAT) | ₹1,014 million | 31% growth; highest reported PAT in Company's history since listing. |
| Operating Cash Flows | ₹1,431 million | Up from ₹873 million in FY2025 (approx. 64% year-on-year improvement). |
| Diluted EPS | ₹30.88 | 31% improvement over the prior year. |
| Dividend Recommendation | ₹2/- per share | Based on face value of ₹5/-. |
The reported PAT of ₹1,014 million included a fair valuation gain on the investment in Apulki Healthcare Private Limited, amounting to ₹221.75 million. The significant increase in operating cash flows to ₹1,431 million, compared to ₹873 million in FY2025, was attributed to structural improvements in the collections framework and working capital management, according to the management.
Focus on Retail Diagnostics Growth
Mitesh Dave, Group CEO, noted that FY2026 marks a pivotal period for Krsnaa Diagnostics, primarily due to the accelerated emergence of the retail diagnostics vertical, Krsnaa Retail Private Limited. He stated that this vertical has become a structurally important and independently scalable growth engine for the Group.Dave highlighted the remarkable growth trajectory of the retail vertical. Within just twelve months of focused scaling, the segment recorded an 8 times jump in revenue and a 7 times surge in touchpoints. The retail network has successfully expanded to 3,500 locations across 5 states, solidifying Krsnaa Retail's position as a formidable player in the country’s retail diagnostics sector.
The company remains committed to building a platform that delivers enduring value to stakeholders. The board's recommendation of a final dividend of ₹2/- per share, coupled with a well-defined and well-funded growth roadmap, anchors the future strategy. Moving into FY2027, the group remains focused on disciplined execution, transparency, and maintaining strong governance standards.
KRSNAA Stock Price Movement
On Monday, Krsnaa Diagnostics Limited shares slipped by 2.23% to close at ₹553.85. The stock shed ₹12.55 on the day, executing a total traded volume of 65,630 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.